Adcendo is a Danish therapeutics company developing antibody-drug conjugates (ADCs) for the treatment of complex cancers including metastatic soft tissue sarcoma (STS).

ADCs are a class of highly potent biopharmaceutical drugs, chemically linking biologically active drugs or cytotoxic compounds to antibodies. These drugs combine the unique and sensitive targeting capabilities of antibodies, with the potent effects of the conjugated cytotoxic drugs, allowing sensitive discrimination between healthy and cancer tissues. Adcendo’s innovative approach has the potential to significantly improve historically limited survival rates in patients with various types of metastatic STS, an estimated 15,000 beneficiaries annually in the EU and US.

With Gilde Healthcare’s support, Adcendo raised €51m ($62m) in Series A financing to establish a pipeline of ADCs directed at novel cancer targets. This round of funding also aimed to bring the lead program to proof of concept in soft tissue sarcoma patients, specifically targeting the novel cancer target uPARAP/Endo180.